Format

Send to

Choose Destination
Metabolites. 2019 Mar 8;9(3). pii: E48. doi: 10.3390/metabo9030048.

Metabolomics Contributions to the Discovery of Prostate Cancer Biomarkers.

Author information

1
Drug Discovery Unit, Instituto de Investigación Sanitaria La Fe, Valencia 46026, Spain. ngomez@cipf.es.
2
Joint Research Unit in Clinical Metabolomics, Centro de Investigación Príncipe Felipe/Instituto de Investigación Sanitaria La Fe, Valencia 46012, Spain. ngomez@cipf.es.
3
Laboratory of Molecular Biology, Fundación Instituto Valenciano de Oncología, Valencia 46009, Spain. ngomez@cipf.es.
4
Drug Discovery Unit, Instituto de Investigación Sanitaria La Fe, Valencia 46026, Spain. ayelen_rojas@iislafe.es.
5
Joint Research Unit in Clinical Metabolomics, Centro de Investigación Príncipe Felipe/Instituto de Investigación Sanitaria La Fe, Valencia 46012, Spain. ayelen_rojas@iislafe.es.
6
Drug Discovery Unit, Instituto de Investigación Sanitaria La Fe, Valencia 46026, Spain. arturo_albors@iislafe.es.
7
Joint Research Unit in Clinical Metabolomics, Centro de Investigación Príncipe Felipe/Instituto de Investigación Sanitaria La Fe, Valencia 46012, Spain. arturo_albors@iislafe.es.
8
Laboratory of Molecular Biology, Fundación Instituto Valenciano de Oncología, Valencia 46009, Spain. jalopez@fivo.org.
9
Drug Discovery Unit, Instituto de Investigación Sanitaria La Fe, Valencia 46026, Spain. pineda_ant@gva.es.
10
Joint Research Unit in Clinical Metabolomics, Centro de Investigación Príncipe Felipe/Instituto de Investigación Sanitaria La Fe, Valencia 46012, Spain. pineda_ant@gva.es.
11
Joint Research Unit in Clinical Metabolomics, Centro de Investigación Príncipe Felipe/Instituto de Investigación Sanitaria La Fe, Valencia 46012, Spain. leonor.puchadescarrasco@icr.ac.uk.

Abstract

Prostate cancer (PCa) is one of the most frequently diagnosed cancers and a leading cause of death among men worldwide. Despite extensive efforts in biomarker discovery during the last years, currently used clinical biomarkers are still lacking enough specificity and sensitivity for PCa early detection, patient prognosis, and monitoring. Therefore, more precise biomarkers are required to improve the clinical management of PCa patients. In this context, metabolomics has shown to be a promising and powerful tool to identify novel PCa biomarkers in biofluids. Thus, changes in polyamines, tricarboxylic acid (TCA) cycle, amino acids, and fatty acids metabolism have been reported in different studies analyzing PCa patients' biofluids. The review provides an up-to-date summary of the main metabolic alterations that have been described in biofluid-based studies of PCa patients, as well as a discussion regarding their potential to improve clinical PCa diagnosis and prognosis. Furthermore, a summary of the most significant findings reported in these studies and the connections and interactions between the different metabolic changes described has also been included, aiming to better describe the specific metabolic signature associated to PCa.

KEYWORDS:

biomarker; early diagnosis; metabolism; metabolomics; prognosis; prostate cancer

Supplemental Content

Full text links

Icon for Multidisciplinary Digital Publishing Institute (MDPI) Icon for PubMed Central
Loading ...
Support Center